Zanolimumab: Difference between revisions
Content deleted Content added
No edit summary |
Updating {{drugbox}} (changes to verified fields - updated 'UNII_Ref', 'ChemSpiderID_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEMBL_Ref', 'KEGG_Ref') per Chem/Drugbox validation (report [[Wikip |
||
| Line 1: | Line 1: | ||
{{drugbox |
{{drugbox |
||
| Verifiedfields = changed |
|||
| verifiedrevid = 380052280 |
| verifiedrevid = 380052280 |
||
| type = mab |
| type = mab |
||
| Line 11: | Line 12: | ||
| PubChem = |
| PubChem = |
||
| DrugBank = |
| DrugBank = |
||
| KEGG_Ref = {{keggcite|changed|kegg}} |
|||
| KEGG = D06356 |
| KEGG = D06356 |
||
| chemical_formula = |
| chemical_formula = |
||
Revision as of 06:03, 21 January 2011
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | CD4 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| KEGG | |
| Chemical and physical data | |
| Molar mass | 147 kDa |
  (what is this?) (verify) | |
Zanolimumab (expected trade name HuMax-CD4[1]) is a human monoclonal antibody and an immunosuppressive drug. It is being developed for the treatment of rheumatoid arthritis, psoriasis, melanoma [2], cutaneous and peripheral T-cell lymphoma.[3][4]
References
- ^ Genmab initiates Phase II Study with HuMax-CD4
- ^ http://www.tenxbiopharma.com/development.shtml
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Zanolimumab, American Medical Association.
- ^ Clinical trial number NCT00042406 for "Trial With HuMax-CD4 in Patients With Rheumatoid Arthritis Failing Treatment With Methotrexate and a TNF-Alpha Blocker" at ClinicalTrials.gov
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |